Achieve Life Sciences

Historical price data

Achieve Life Sciences is a late-stage specialty pharmaceutical company with a mission to end the global nicotine dependence epidemic. Its strategy is centered on cytisinicline, a plant-based alkaloid with a novel dual agonist/antagonist mechanism for smoking cessation. The company has successfully completed its Phase 3 program, submitted an NDA to the FDA in June 2025, and received a PDUFA target action date of June 20, 2026. If approved, cytisinicline could become the first new FDA-approved treatment in this category in 20 years, targeting a multi-billion dollar market with significant unmet need.

Focused development of cytisinicline, a plant-based alkaloid with a novel dual partial agonist/competitive antagonist mechanism targeting the α4β2 nicotinic acetylcholine receptor for smoking cessation.

Cytisinicline competes primarily against varenicline (Chantix®), which has efficacy but tolerability limitations, and over-the-counter nicotine replacement therapies (NRT) with lower efficacy. Its key differentiation is a favorable tolerability profile, particularly low nausea, which could drive superior patient adherence and market share capture.